AbCellera reports positive phase 1 data for menopause drug ABCL635

May 11, 2026 4:05 PM

AbCellera Biologics Inc. (NASDAQ: ABCL) reported positive interim Phase 1 clinical trial results for ABCL635, an experimental antibody treatment for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found